Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2017 04:17 ET | Source: Esperite N.V.

Esperite (ESP) confirme le développement positif de ses activités génétiques et annonce son intention de réclamer 5,2 millions de dommages-intérêts à Premaitha (NIPT)

Zutphen, les Pays-Bas, 15 mai 2017 La dernière action de Premaitha contre Genoma démontre sa tentative désespérée de cacher au public la situation financière de Premaitha. L'effet de leur action...
May 15, 2017 01:17 ET | Source: Esperite N.V.

Esperite (ESP) confirme le développement positif de ses activités génétiques et annonce son intention de réclamer 5,2 millions de dommages-intérêts à Premaitha (NIPT)

Zutphen, les Pays-Bas, 15 mai 2017 La dernière action de Premaitha contre Genoma démontre sa tentative désespérée de cacher au public la situation financière de Premaitha. L'effet de leur action...
May 15, 2017 01:17 ET | Source: Esperite N.V.

Esperite (ESP) - Esperite confirms the positive development of its current and future genetic activities and announces its intentions to claim 5.2 Million euro damages against Premaitha (NIPT)

Zutphen, The Netherlands, 15 May 2017 Premaitha's latest action against Genoma demonstrates its desperate attempt to conceal Premaitha's financial situation. The effect of their legal action...
May 15, 2017 01:17 ET | Source: Esperite N.V.

Esperite (ESP) - Il Gruppo conferma lo sviluppo positivo delle sue attività genetiche presenti e future e annuncia l'intenzione di richiedere 5.2 milioni di euro a Premaitha (NIPT) per danni

Zutphen, Paesi Bassi, 15 maggio 2017 Le ultime mosse di Premaitha contro Genoma, dimostrano il suo disperato tentativo di nascondere la situazione finanziaria di Premaitha stessa. L'effetto...
May 11, 2017 03:27 ET | Source: Esperite N.V.

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology

Esperite (ESP): Patent granted in China for treatment of acute and chronic inflammatory and autoimmune diseases with EVs technology. The Cell Factory expands its patent...
May 05, 2017 03:07 ET | Source: Esperite N.V.

Esperite (ESP), The Cell Factory demonstrate anti-inflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

Esperite's (Euronext: ESP) biotech subsidiary The Cell Factory develops extracellular vesicles (EVs) biologic drug (CF-MEV-117) for treatment of drug-resistant epilepsy in children. The consortium...
April 26, 2017 01:17 ET | Source: Esperite N.V.

ESPERITE delays publication of 2016 Annual Report

Zutphen, The Netherlands - 26 April 2017 Esperite N.V. (Euronext: ESP, the "Company" or "Esperite") announces that additional time is needed for the Company to publish its Annual Report for the...
April 25, 2017 01:17 ET | Source: Esperite N.V.

ESPERITE N.V. (ESP) WITH CRYOSAVE CONTRIBUTES TO TREATING A 9 YEAR OLD CHILD WITH THALASSEMIA MAJOR IN SWITZERLAND

CryoSave confirms the importance of cord blood stem cells in regenerative medicine. Last week, CryoSave released a cord blood stem cell unit from the state of the art laboratory in Geneva for the...
April 24, 2017 01:17 ET | Source: Esperite N.V.

ESPERITE's shareholders approved the external financing of up to EUR 13 million

Reports On Extraordinary General Meeting Of Shareholders Zutphen, The Netherlands - 24 April 2017 Esperite N.V. (Euronext: ESP, "Esperite") announces that at its Extraordinary General Meeting of...
March 31, 2017 16:06 ET | Source: Esperite N.V.

CryoSave e Crioestaminal chegaram a um acordo para a armazenagem das células estaminais da Bioteca

CryoSave e Crioestaminal chegaram a um acordo para a armazenagem das células estaminais da Bioteca Porto, Portugal - 1 março de 2017 CryoSave decidiu asegurar a armazenagem da sua subcontratada...